Lipid-lowering drugs—such as ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and Icosapent ethyl—have been found to elicit cardiovascular risk reduction in T2DM patients, but data on T1DM patients are currently lacking. The gene discussed is PCSK9; the disease is type 1 diabetes mellitus.